TMCnet News
Nippon Shinyaku, INNOVIVE Pharmaceuticals Conclude Licensing Agreement for NS-187, Drug Candidate for Chronic Myelogenous Leukemia(Comtex Business Via Thomson Dialog NewsEdge)Tokyo, Japan, Jan 06, 2006 (JCN Newswire via COMTEX) --Nippon Shinyaku announced on January 5 that it concluded a licensing agreement with INNOVIVE Pharmaceuticals of New York on December 28, 2005. Under the agreement terms, INNOVIVE Pharmaceuticals will be licensed to exclusively develop and market NS-187, a drug candidate developed by Nippon Shinyaku, worldwide except in Japan. NS-187, which is a molecular targeted agent in the preclinical stage, is intended for the treatment of chronic myelogenous leukemia (CML). It is estimated that about 63,000 people in the world, of whom about 8,000 people live in Japan, have CML. [ Back To TMCnet.com's Homepage ] |